Chem Financing to Remain Challenged (ICIS Chemical Business August 18 – August 24, 2023)Jonathan Choi2023-09-18T19:55:08+00:00August 24th, 2023|Featured, Our Publications|
Chemical M&A Activity Turns Up (ICIS Chemical Business August 11 – August 17, 2023)Jonathan Choi2023-09-18T19:55:40+00:00August 11th, 2023|Featured, Our Publications|
Young & Partners Biotech Financing Review and Outlook (June 21, 2023)Jonathan Choi2023-06-26T19:39:49+00:00June 21st, 2023|Our Publications|
Young & Partners Chemical M&A Review and Outlook (June 5, 2023)Jonathan Choi2023-06-21T19:49:37+00:00June 5th, 2023|Our Publications|
Young & Partners Pharma M&A Review and Outlook (June 2, 2023)Jonathan Choi2023-06-21T19:35:37+00:00June 2nd, 2023|Our Publications|
Young & Partners Biotech M&A Review and Outlook (June 2, 2023)Jonathan Choi2023-06-21T19:39:17+00:00June 2nd, 2023|Our Publications|
Biopharma M&A: Year in Review, Ripples Ahead (Pharmaceutical Executive, March 2023)Jonathan Choi2023-03-14T19:28:18+00:00March 14th, 2023|Featured, Our Publications|
Debt Financing to be difficult in 2023 (ICIS Chemical Business February 3 – February 9, 2023)Jonathan Choi2023-02-08T02:20:40+00:00February 3rd, 2023|Featured, Our Publications|
Young & Partners Pharma and Biotech M&A Review and Outlook (January 20, 2023)Jonathan Choi2023-01-26T15:10:20+00:00January 20th, 2023|Featured, Our Publications|
Young & Partners Chemical M&A Review and Outlook (January 17, 2023)Jonathan Choi2023-01-26T15:10:48+00:00January 17th, 2023|Featured, Our Publications|
